Carvykti, Janssen Pharmaceutical’s treatment for refractory multiple myeloma has been approved by the FDA. Jannsen’s first cell therapy is for treatment of adults and comes under the larger parent company Johnson & Johnson.
Janssen’s Cavykti provides the treatment through the mechanism of genetically modified T-cell-based immunotherapy.
Cavykti’s U.S. FDA approval was the result of successful clinical trials. The clinical trials were of CARTITUDE-1 where ciltacabtagene autoleucel (Cavykti) was tested for patients of myeloma.
The trial yielded promising results and the two-year post-trial follow up found that Cavykti’s component medicine showed long-lasting effects which led to the FDA approval with over 95% of participants exhibiting a response.
The drug itself is a B-cell maturation antigen that can be used for multiple options of therapy. These include use as an anti-CD38 monoclonal antibody, immunomodulatory agent and as a proteasome inhibitor.
The drug trial leading to FDA approval involved the 97 participants being given 6 regimes of the treatment. Each participant progressed after the last dose of treatment was given.
The data findings for Cavykti show that participants of the trial positively reacted to ciltacabtagene autoleucel and they showed a long-lasting response from a single treatment. In fact, at the 22-month check-in, most showed this continued response while a stringent complete response was seen in over 80% of patients.
Further, the clinical trials are evaluating the efficacy and long-lasting safety of the medicine.
